Drooling, dysphagia and upper-aerodigestive disorders — formative SAQs

SAQ 1 (10 marks)

A 7-year-old boy with severe cerebral palsy (Gross Motor Function Classification System level V) is reviewed in the neurodisability clinic. He has persistent drooling that soaks several bibs a day and has caused perioral skin breakdown, and he has had three lower-respiratory tract infections in the last year. His parents report mealtimes take over an hour, he coughs on thin fluids, and his voice often sounds wet after drinking. Oromotor therapy and postural management have produced limited improvement. [5] [7]

1. Define drooling (sialorrhoea) and explain the usual mechanism in cerebral palsy, distinguishing it from hypersalivation. (3) [5]
2. Outline your stepwise management of his drooling, naming each rung of the ladder and giving the first-line pharmacological agent with its monitoring. (4) [1] [2]
3. What features suggest his swallow is unsafe, and how would you confirm aspiration including the silent form? (3) [7] [9]

Model answer — SAQ 1

(1) Definition and mechanism (3). Drooling (sialorrhoea) is the unintentional loss of saliva from the mouth. In cerebral palsy it is, in the large majority of children, a problem of handling and clearing a normal volume of saliva — poor lip seal, discoordinated and infrequent swallowing, reduced oral sensory awareness and poor head and trunk control — rather than overproduction; children with neurodisability produce similar or smaller volumes of saliva than their peers. This distinguishes it from true hypersalivation, which arises from teething, oral inflammation or dental disease, gastro-oesophageal reflux, or drugs such as antipsychotics and cholinergic agents, and which is managed by treating the cause. [5]

(2) Stepwise management (4). I would climb the drooling ladder and step up only as far as needed. (a) Non-pharmacological: optimise posture and head control, treat nasal obstruction and mouth breathing, maintain oral hygiene and dental care, and provide skin protection and bibs. (b) Oromotor and swallow therapy: speech-language therapy for lip closure, tongue control, oral sensory awareness and swallow frequency. Because these have had limited effect, I would (c) start pharmacological saliva reduction with an anticholinergic — glycopyrrolate (glycopyrronium) orally, weight-based and titrated — which is the best-studied first-line agent. I would obtain a baseline swallow and chest assessment and repeat it, because anticholinergics thicken secretions and can paradoxically worsen swallow and airway clearance. (d) Botulinum toxin into the submandibular (and, where needed, parotid) glands is the next step, effective for around three to four months and repeatable, and (e) surgery (submandibular duct relocation, with or without submandibular gland excision) is reserved for refractory or predominantly posterior disease. [1] [2]

(3) Unsafe swallow and confirming aspiration (3). The features suggesting an unsafe swallow are coughing on thin fluids, a wet or gurgly voice after drinking, prolonged effortful meals, and recurrent lower-respiratory infections — and, importantly, the possibility of silent aspiration, in which there is no protective cough and the only clues are recurrent chest infections, chronic lung change and faltering growth. I would perform a clinical swallow evaluation and then an instrumental study: a videofluoroscopic swallow study (VFSS) to assess all phases, detect penetration and aspiration including silent aspiration, and test compensations (texture, posture, bolus size), with fiberoptic endoscopic evaluation of swallowing (FEES) as a bedside complement for secretion management. [7] [9]